Thermo Fisher Scientific has launched its $11.5-billion takeover offer for Qiagen, a provider of molecular diagnostics and sample preparation technologies. Thermo Fisher had previously announced the proposed acquisition earlier this year (March 2020). The offer, priced at EUR 39 ($43) per share, began this week (May 18, 2020) and is scheduled to end on July 27, 2020.

The Qiagen Managing Board and Supervisory Board have unanimously recommended that Qiagen shareholders accept the tender offer by tendering their shares and vote in favor of each of the transaction resolutions at the company’s General Meeting.

The transaction is expected to close in the first half of 2021.

Source: Thermo Fisher Scientific